Lupin Ltd press release
Lupin Limited has launched Raltegravir Tablets USP, 600 mg in the United States on November 3, 2026, following U.S. FDA approval of its Abbreviated New Drug Application.
By ScoutQuest · · 1 min read
- Product Launched
- Raltegravir Tablets USP, 600 mg in the United States on November 3, 2026
- IQVIA Annual Sales Estimate
- USD 26 million in the U.S. (IQVIA MAT September 2026)
- Reference Listed Drug
- Isentress HD Tablets, 600 mg of Merck Sharp & Dohme, LLC
- Release
- Launch / capacity
📌 Lupin says Raltegravir Tablets USP, 600 mg are bioequivalent to the reference listed drug Isentress HD Tablets, 600 mg of Merck Sharp & Dohme, LLC, and are indicated for HIV-1 infection in adults and in pediatric patients weighing at least 40 kg.
📌 IQVIA MAT September 2026 estimates annual sales of USD 26 million in the U.S. for Raltegravir Tablets USP, 600 mg (RLD Isentress HD), the company cites.
Also from Lupin
Lupin Q2 FY27 investor presentation: sales up 14.0% YoY, EBITDA margin down to 25.1%
4 Nov 2026
Lupin Q2 FY2027: EBITDA falls 10.7% YoY to INR 21,712 Mn, EBITDA margin narrows 770 bps to 27.9%
4 Nov 2026
Q2/H1 FY27 results approved; consolidated net profit ₹11,553.0 million, standalone loss ₹59.1 million
4 Nov 2026
More numbers
- Estimated annual U.S. sales, Raltegravir 600 mg (IQVIA MAT September 2026)USD 26 million
- Generic exclusivity period, Raltegravir 600 mg180-day
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.